This Medudy course is a video tutorial for physicians on the topic “PTEN Deficiency in Metastatic Hormone-Sensitive Prostate Cancer: Clinical Relevance and Unmet Medical Needs.”
In this video, Prof. Markus Eckstein of the Institute of Pathology at Erlangen University Hospital discusses the clinical significance of PTEN alterations in metastatic hormone-sensitive prostate cancer (mHSPC). The loss of the tumor suppressor PTEN permanently activates the PI3K/AKT signaling pathway and promotes a more aggressive course of the disease; this affects about one-quarter of patients with newly diagnosed mHSPC.
FISH and NGS are available for testing to identify genomic alterations, as is immunohistochemistry for the direct detection of the PTEN protein. Against this backdrop, there is a significant unmet medical need and, at the same time, a promising avenue for targeted therapies, which requires reliable determination of PTEN status in clinical practice.
Note: All “speakers” appearing in the Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. The video content was created and reviewed by the editorial team with the aid of AI, based on high-quality scientific sources, and has been approved by the speakers.
This course was made possible with the generous support of AstraZeneca.
By the end of this course, you will know:
- How PTEN Works
- The Clinical Significance of PTEN Alterations in mHSPC
- Method for Determining PTEN Status
- the high unmet medical need in the treatment of mHSPC
